Axsome Therapeutics Inc

Medical Writer I (Remote)

United States

Not SpecifiedCompensation
Entry Level & New Grad, Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Biopharmaceutical, Pharmaceutical, BiotechnologyIndustries

Requirements

Candidates should possess an advanced degree in a scientific discipline (PhD, PharmD, or MS) with 0-1 year of medical writing experience in the pharmaceutical industry, or a Bachelor's degree in a scientific discipline with 2+ years of experience at a pharmaceutical or biotechnology company or CRO. Demonstrated ability to communicate and write clearly, concisely, and effectively, with an aptitude for data compilation, analysis, and presentation, is essential. A basic understanding of biostatistics reporting standards and associated concepts, attention to detail in fact-checking, logical flow, parallelism, formatting, and document structure, and proficiency with Microsoft Office and electronic document templates are required. Excellent verbal and written communication skills, along with the ability to work independently and collaboratively in a fast-paced, matrixed team environment, are also necessary.

Responsibilities

The Medical Writer I will provide technical and operational support for scientific writing activities and projects, including authoring, editing, and contributing to nonclinical and clinical documents, regulatory submission documents, presentations, posters, publications, and regulatory fulfillment. This role involves cross-functional collaboration with internal departments and external resources on scientific writing matters. The incumbent will work with multifunctional teams to prepare documents such as nonclinical reports, clinical study reports (CSRs), protocols, protocol amendments, briefing documents, Investigator Brochures (IBs), safety updates, agency responses, and summary modules under strict timelines, supporting key regulatory submissions to US and global health authorities. Responsibilities also include ensuring clarity and consistency of key messages within and across documents, assisting with strategic and scientific contributions at the project and/or study team level, providing editorial or review support for abstracts, manuscripts, posters, and presentations, and collaborating with cross-functional team members to ensure accurate and timely completion of high-quality, scientifically justified documents. The role requires ensuring consistent document presentation style, assisting in day-to-day operational activities, and performing other assignments as specified by management.

Skills

Medical Writing
Scientific Writing
Regulatory Submissions
Clinical Documents
Good Clinical Practice (GCP)
ICH Guidelines
Nonclinical Reports
Clinical Study Reports (CSRs)
Protocols
Investigator Brochures (IBs)
Safety Updates
Agency Responses
Editing
Authoring

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI